Phase 1 Study Explores Combined Pharmacokinetics of Bimagrumab and Tirzepatide
A Study of Bimagrumab Alone (LY3985863) and Bimagrumab With Tirzepatide (LY900042) in Healthy Participants
Background
While bimagrumab targets muscle growth and fat loss, and tirzepatide is highly effective for type 2 diabetes and obesity via GIP/GLP-1 agonism, their combined therapeutic potential is significant. Understanding the pharmacokinetic interactions and bioavailability of their co-administration or co-formulation is a critical knowledge gap that needs to be addressed for future clinical development.